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Abstract
A healthy sphincter physiology is a complex interplay between neural and
muscle population, responsible for relaxation and contraction, which allow feces to
pass and reestablishment of closure. The loss of integrity of neuromuscular func-
tionality or cellular component results in fecal incontinence (FI). The current avail-
able treatments have been disappointing in long-term relief. This chapter represents
a regenerative medicine approach to this debilitating disease, wherein a new
internal anal sphincter (IAS) BioSphincter™ is bioengineered from the patient’s
own cells and implanted. It results in long-term restoration of the cellular integrity
and reinstatement of the physiological function of the IAS. Following implantation
in rodents, the engineered sphincters became vascularized and maintained their
phenotype and functionality. The developed IAS BioSphincter™ were validated to
treat the FI in large animals and successfully restored anorectal functionality.
According to NIH/NIDDK, one out of seven people report to health care providers
complaining of fecal incontinence. This chapter elucidates the long road in devel-
oping on implantable bioengineered IAS “BioSphincter™” that would benefit and
improve the quality of life of a large socially distressed segment of the population.
Keywords: fecal incontinence, regenerative medicine, BioSphincters, neural
progenitor cells, anorectal physiology
1. Introduction
A healthy anorectal functionality is a coordinated interplay between the enteric
nervous system, smooth muscle of internal anal sphincter (IAS), striated external
anal sphincter and puborectalis muscles [1]. Anomalies in any of this individual or
group of tissues may lead to anorectal irregularities and diseases [2]. Fecal inconti-
nence (FI) is devastating from a hygiene perspective due to involuntary soiling of
liquid and solid stool and results in the distressing psychosocial impact on the
patient [3]. Injury to the perineum may also result in the complete or partial
destruction of the anal sphincter and distal rectum potentially resulting in persistent
incontinence [4]. The resulting psychological stress, social stigma, decreased self-
esteem and productivity can be overwhelming. In the USA, men and women suffer
from FI equally with a range of 2–6% in people aged 20–30 years. The prevalence
increases to over 15% in people older than 70 years [5].
Clinical characteristics of FI have been correlated with underlying sphincter
pathology [1]. In the classical FI, the pelvic floor muscles are dysfunctional (due to
muscle or nerve damage) and result in the frequent urge of incontinence. The urge
of incontinence is mainly due to external anal sphincter defects and lower anorectal
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squeeze pressures. Patients with the urge of incontinence have FI episodes with
awareness of the event but cannot prevent it because of the inability to increase
anorectal pressures [1, 6, 7].
The passive FI caused an isolated or combined loss of smooth muscle function
(IAS), skeletal muscle function (EAS), anorectal sensory mechanisms or neural
control [8, 9]. It leads to loss of the sense that rectum is full and results in unknow-
ingly leakage of stools, mucus, and flatus. Passive incontinence occurs without the
patient’s awareness of the event until after incontinence has occurred [6]. Patients
with passive incontinence are more likely to have internal anal sphincter defects
and lower anorectal resting pressures. The anal resting tone is produced by the
internal anal sphincter (IAS) and the external anal sphincter. The IAS contributes
60–70% of the anal tone [10]. In addition, patients with passive incontinence have
been shown to have more frequent and exaggerated IAS relaxation compared to
continent controls [11]. Patients with FI have been shown to have variable loss of
the Recto Anal Inhibitory Reflex (RAIR) [12].
Currently, there is no satisfactory long-term treatment for FI. Epidemiological
studies indicated that most patients suffering from FI do not consult to clinicians
and depend on self-management or rely on the use of adult diapers. The classical
treatment of FI becomes more involved in accordance with the extent and severity
of the incidences of incontinence.
Conservative management of FI is usually initiated with educating the patients
with behavioral techniques. These techniques such as scheduling toileting and pre-
ventive strategies [13]. The next step is the incorporation of dietary changes using
fiber supplements or laxative to normalize stool consistency [14]. Along with die-
tary modulations, antidiarrheal drugs, alpha (1 and 2) receptor agonists could also
be used to control the frequency of FI episodes [15]. Pelvic floor muscle exercise and
biofeedback are other conservative methods to manage initial stages of FI. Biofeed-
back methods are behavioral management that incorporates electronic and
mechanical devices to emphasize bowel and muscle retraining. Pelvic floor muscle
exercises with biofeedback improve sense and strength of pelvic floor muscles for
contraction during rectal distention and uncontrollable urge of FI [16, 17].
According to an observational study, these conservative methods resulted in 50%
reduction in the frequency of FI and 21% adequate relief in FI [13]. The effective-
ness and success of these measures may help in the management of mild cases of FI.
If the patient does not improve with the mentioned conservative methods, the
patient is offered advanced therapies. Advanced therapies are more invasive and
involve different levels of surgical interventions such as electrical stimulation,
sphincteroplasty, injection of bulking agents, and implantable devices. Sacral nerve
and tibial nerve stimulation found to be more effective than electrical stimulation of
muscles [18–20]. In a randomized controlled trial on patients with structurally
intact and innervated sphincters, the implantation of a battery-operated stimulator
was found to be effective from 36 to 50% [18, 19]. The frequency of episodes of FI
was reduced during stimulation, but unaffected without stimulation or similar to
sham [13]. The implantable devices such as artificial bowel sphincter [21], magnetic
beads [22] and synthetic polymer rings are implanted around the anal canal to
augment the pressure. There is a lack of randomized controlled trial towards long-
term safety and efficacy of these procedures. The sphincteroplasties (suturing of the
separated sphincter) and graciloplasty (wrapping of gracilis muscle around the anal
canal) are another class of surgical procedures to treat FI. These procedures have
shown varying rates of success and high chances of obstructed defecation. Inert
materials (silicone elastomers, ceramic beads) or biopolymers (polycaprolactam
beads) as bulking agents injected around the anal canal to increase resting pressure
[23]. There was no specific success reported regarding long-term efficacy.
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However, a 3-month follow up study of injection of dextranomer microspheres
resulted in a 50% reduction in FI frequency in 52% patients [24].
Cell delivery is advanced translation method for long-term efficacy in FI. Stem cell
constructs were developed, and were able to generate smooth muscle tone but lacked
innervation [25]. Autologous transplantation of muscle progenitor cells into the
sphincters exhibited potentials for re-stabilization of myogenic functionality in the anal
sphincters [26]. Delivery of autologous human adipose-derived stem cells in poorly
functioning sphincter muscle as replacement of fibrous tissues acted as a mechanical
support for physiological functions [27]. Injection of autologous myoblasts into the
external anal sphincter defect also resulted as a safe and promising approach to improve
symptoms of FI induced owing to obstetric anal sphincter trauma [28]. Sphincters are
complex organs for cell delivery. There are several challenges to overcome in direct cell
delivery, such as specific types and dosages of cells, circular distribution and orientation
of cells around the anal canal after injection, functional integration with host cells and
long-term effects such as biodistribution, tumorigenicity.
Current cell delivery technologies focus either on the reinstatement of the striated
muscle of the external anal sphincter or mechanical support to the sphincter, with
little attention on the reinstatement of IAS function [29–32]. The terminal gut func-
tion requires coordinated contraction and relaxation of the smooth muscle of rectum
mediated through the enteric nervous system of IAS [2, 6]. To remedy an injured
anus, it is imperative to reinstate both smoothmuscle and intrinsic neural components
of IAS. We describe the evolution of a regenerative medicine approach proposed to
provide critical components to reinstate function in the anorectum and remedy pas-
sive fecal incontinence caused by injury to the IAS. According to this hypothesis,
implantation of engineered autologous BioSphincters reinstate IAS function and
restore fecal continence. Autologous smooth muscle and neural progenitor cells from
gut biopsies were used to bioengineer intrinsically innervated IAS [33, 34]. Autolo-
gous functional intrinsically innervated IAS construct was successfully implanted into
healthy animal models. Following implantation in rodents, the engineered sphincters
became vascularized and maintained their phenotype and functionality [35–38]. A
large animal model of passive fecal incontinence was developed and demonstrated
sustained restoration of fecal continence, and restoration of basal tone and restoration
of RAIR after implantation of engineered autologous, intrinsically innervated internal
anal sphincter (IAS) BioSphincters [10, 39] (Figure 1).
Figure 1.
Regenerative medicine approach to treat fecal incontinence using autologous bioengineered BioSphincter.
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This chapter summarizes the regenerative medicine approach of bioengineering
of BioSphincters, including developmental stages of the technology, challenges,
process optimization, characterization, detail pre-clinical evaluation of the
BioSphincter towards the treatment of FI.
This chapter encompasses both in vitro and in vivo studies designed to support the
safety and efficacy of bioengineered sphincters. Studies performed in vitro include
the generation of three-dimensional internal anal sphincter models using rabbit IAS
smooth muscle cells and human IAS smooth muscle cells. The in vitro studies also
describe the intrinsical innervation of bioengineered IAS sphincters. Studies
performed in vivo are described in two parts, small animal rodent studies and a large
animal, rabbit fecal incontinent model. Small animal rodent studies included: (1)
generation and implantation of IAS smooth muscle cell sphincter into a C57BL/6 J
rodent; (2) generation and implantation of human innervated bioengineered sphinc-
ters into an athymic rodent model, at subcutaneous and peri-anal sites. Large animal
studies demonstrating successful implantation of intrinsically innervated autologous
IAS BioSphincters were conducted in a rabbit model of fecal incontinent.
2. Bioengineering an in vitro three-dimensional physiological model
of the internal anal sphincter from rabbit smooth muscle cells
The objective of the early studies was to develop an in-vitro three-dimensional
(3-D) physiological model of the IAS smooth muscle cells. In this initial attempt,
rabbit origin IAS smooth muscles were cultured on top of a loose fibrin gel; subse-
quently, these cells migrated and self-assembled in circumferential alignment. As
the cells matured, the fibrin gel contracted around a 5-mm-diameter silicon mold,
resulting in a 3-D cylindrical ring of sphincteric tissue [40].
Histological analysis exhibited a gradient of cell alignment in the bioengineered
IAS sphincters. The engineered sphincters were analyzed for physiological func-
tionality using an isometric force transducer. Constructs were placed between a
stationary central pin and the measuring arm of the organ bath transducer (Harvard
Apparatus, Holliston, MA). The bioengineered sphincter generated a spontaneous
basal tone, and treatment with 8-bromo-cAMP (8-Br-cAMP) resulted in relaxation.
In the next step, agonist-induced stimulation (using acetylcholine) resulted in cal-
cium- and concentration-dependent peak contraction. This effect was diminished
by the addition of 8-Br-cAMP. Similar bioengineered IAS sphincters were also
generated using colonic smooth muscle cells. IAS constructs display significant
differences in functionality compared to colonic smooth muscle cells constructs,
which confirmed tissue specificity and functionally to IAS [40].
This was the first successful attempt to develop 3-D in vitro model of engineered
IAS sphincters using smooth muscle cells of IAS. Bioengineered IAS sphincters
displayed circular cell alignment and physiological functionality. The functionality
and physiological response in engineered tissues exhibited similarity to IAS smooth
muscle in vivo [38].
3. In vivo cytocompatibility and functionality analysis on subcutaneous
implantation of physiologically functional bioengineered internal
anal sphincter
After successful bioengineering an IAS specific sphincter tissues, the next goal was
to evaluate the in vivo biocompatibility and adverse reaction. The objective of these
studies was to test the post-implantation functionality of bioengineered sphincters
engineered using IAS smoothmuscle cells.Table 1 summarized the detail study design.
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In this endeavor, smooth muscle cells were isolated from the IAS of donor
C57BL/6 mice. Smooth muscle cell constructs were engineered on Sylgard coated
plates using fibrin gel, as described previously [40]. The engineered constructs
were successfully implanted into the subcutaneous region of same strain mice and
treated with either fibroblastic growth factor-2 or saline as controls using a micro-
osmotic pump. Mice were euthanized after 4 weeks, and the implant was harvested.
The implant was intact, healthy in color without any degradation, and interestingly
displayed muscle attachment to the back of the mouse, with neovascularization.
Constructs exhibited no external sign of inflammation, fibrosis, or infection,
because of the use of syngeneic tissue. The supplement of FGF-2 also helped in
tissue viability, cellular integrity, and vascularization. The harvested tissues
maintained smooth muscle alignment and phenotype [37, 38].
The post-implant harvested constructs were analyzed for force generation. The
harvested implants generated and maintained the spontaneous basal tone in the
absence of any external stimuli. The developed tone confirmed the integrity of ionic
membrane characteristics, membrane receptors and their intracellular signaling
mechanisms for contraction and relaxation. On treatment of a relaxing stimulant
such as a vasoactive intestinal peptide (VIP), the force and magnitude of relaxation
were consistent before and after implantation. The rapid, and dose-dependent
sustained (over 30 min without signs of muscle fatigue) contractions on the treat-
ment of acetylcholine and phorbol dibutyrate was elicited as well. The physiological
studies confirmed that implanted bioengineered sphincters maintain IAS physio-
logical functionality after implantation [37, 38].
In summary, IAS sphincters using smooth muscle tissue could be bioengineered.
The bioengineered sphincters were cytocompatibility, functional, without any
adverse reaction and had potential to be used as a graft for dysfunctional internal
anal sphincter [37, 38].
Steps Study objective(s) Test article Animal
model
Key outcome (e.g., safety
(tumor/tox/biodistribution),
efficacy, characterization,
stability, degradation)
Study purpose: cell isolation
Isolation of
SMC
To isolate IAS smooth
muscle cells (SMC) and
characterization of
smooth muscle
In vitro
expanded IAS
smooth
muscle cells
C57BL/
6J mice
Smooth muscle cells expressed
cell lineage appropriate
phenotype markers
Study purpose: bioengineered sphincters
Bioengineering
sphincters with
smooth muscle
Characterize the
bioengineered
sphincters
Bioengineered
sphincters
C57BL/
6J mice
Formation of stable sphincters
Study purpose: implantation of bioengineered sphincters into rodent
Implantation of
bioengineered
sphincters
Optimization of the
implantation procedure
Bioengineered
sphincters
C57BL/
6J mice
Bioengineered sphincters were
implanted subcutaneously on
syngeneic mice (C57BL/6J)
model
Study purpose: end points analysis
Bioengineered
sphincters
histopathology
Analysis of fibrosis/
inflammation and
functional activity
Implanted
bioengineered
sphincters
C57BL/
6J mice
No fibrosis or inflammation was
observed in bioengineered
sphincter implants
Table 1.
Summary of nonclinical study for safety and efficacy of bioengineered sphincters in C57BL/6J mice.
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4. Bioengineering an internal anal sphincter derived from smooth
muscle cells isolated from the human internal anal sphincter
The preliminary work in the previous sections using SMCs harvested from
animal models confirmed the feasibility of engineering functional physiologic
IAS constructs and initial biocompatibility. [40]. The next objective was to
validate the feasibility of engineering IAS sphincter constructs from SMCs of
human IAS origin.
Human IAS was received from NDRI and SMCs were harvested following
previously described protocol. At confluency, SMCs were seeded on Sylgard
coated plates with fibrin gel. Cells migrated and aligned circularly around the
Sylgard mold located at the center of the plate. All the 3-D bioengineered
sphincter constructs successfully formed within 5–10 days of seeding of Human
IAS SMCs [34].
The developed human IAS constructs displayed the essential characteristics of a
native functional IAS; the bioengineered IAS constructs able to generate the spon-
taneous myogenic basal tone and respond to different pharmacological agents.
Bioengineered human IAS sphincters also exhibited dose-dependent force genera-
tion in response to different stimulants. The IAS smooth muscle constructs
displayed a tissue-specific basal tone compared to colonic muscle cells. The basal
tone, acetylcholine-induced contraction and PdBU generated were reduced by
calphostin-C but not with Y-27632. The detailed functionality resulted that the
protein kinase C (PKC) pathway (independent of the Rho/ROCK pathway)
appeared to be responsible for IAS specific tone and contractions [34].
The process of bioengineering IAS constructs using human IAS smooth muscles
was highly reproducible. The developed IAS muscle constructs were functionally
similar to native IAS sphincters. This was the first report demonstrating the gener-
ation of a functional in vitro model of human IAS that may be used for the elucida-
tion of mechanisms associated with smooth muscle sphincter myogenic
malfunction and for the investigation of treatments for fecal incontinence [34].
5. Bioengineered IAS generated from human cells and preliminary
biocompatibility and functional analysis after implantation
in an athymic rodent model
In the previous sections, IASmuscle constructs were successfully bioengineered
with animal and human origin IAS circular muscles. The bioengineeredmouse IAS
muscle constructs displayed physiological functionality after implantation in wild type
mice. However, compare to anatomy and physiology of native IAS sphincters, the
bioengineeredmuscle constructs lacked innervation of the neuronal population. There-
fore, the next target in these studies was to intrinsically innervation of bioengineered
IASmuscle constructs and evaluation of cellular viability, physiological functionality,
and safety after implantation.Table 2 summarized the detail study design.
In this effort, the human IAS muscles were harvested and cultured as described
previously. The neuronal cell line was isolated from a D13 embryo from H-2Kb-
tsA58 immortomouse. The bioengineering of constructs was divided into two steps.
In the first step, the isolated neuronal stem cells were mixed with hydrogel and
plated in the Sylgard coated plates. After gelation, IAS origin smooth muscle cells
were mixed with the collagen gel and overlaid to the previous cell-hydrogel. A fully
compacted sphincter-like construct were developed in the first 60 h [35].
The neuronal stem cells differentiation towards functional neurons was carried
out in a specific media targeted to neural differentiation. The bioengineering
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process took 9 days to generate an intrinsically innervated muscle constructs mim-
icking physiological functionality to native IAS tissues. The neural cell differentia-
tion was further confirmed by positive expression of mature excitatory (choline
acetyltransferase; ChAT) and inhibitory (VIP) motor neurons in the quantitative
analysis using PCR. The cross-sections of engineered sphincters were demonstrated
positive immunoreactivity against ChAT and VIP markers. After physiological
functional analysis, the bioengineered sphincter were implanted subcutaneously
into immune suppressed RAG1/ mice for 4 weeks [35].
At harvest, the implanted construct exhibited neo-vascularization without any
symptom of fibrosis or immunogenic reaction. The immuno-histological analysis
confirmed that the sections of the harvested implant displayed reticulated
Steps Study objective
(s)
Test article Animal model Key outcome (e.g., safety
(tumor/tox/
biodistribution), efficacy,
characterization, stability,
degradation)
Study purpose: cell isolation
Isolation of SMC To isolate IAS
smooth muscle
cells (SMC) and
characterization
In vitro
expanded IAS
smooth
muscle cells
Cadaver
human
Smooth muscle cells expressed
cell lineage appropriate
phenotype markers
Isolation of
neural cells from
embryo of
immortomouse
To isolate neural
cells and
characterization
In vitro
expanded
neural cells
h-2kb-tsA58
immortomouse
Neural cells expressed cell
lineage appropriate phenotype
markers
Study purpose: bioengineered sphincters
Bioengineered
Sphincters with
smooth muscle
and neural cells
Characterize the
bioengineered
sphincters
Bioengineered
sphincters
Cadaver
human and h-
2kb-tsA58
immortomouse
• Formation of
intrinsically innervated
sphincters
• Bioengineered
sphincters exhibited
basal tone, relaxation
and contractile activity
Study purpose: implantation of bioengineered sphincters into rodent
Implantation of
bioengineered
sphincters
Optimization of
the implantation
procedure
Bioengineered
sphincters
RAG1/mice Bioengineered sphincters
were implanted
subcutaneously on athymic
mice (RAG1/) model
Study purpose: end points analysis
Bioengineered
sphincters
histopathology
Analysis of
fibrosis/
inflammation
and functional
activity
Implanted
bioengineered
sphincters
RAG1/
mice • No fibrosis or
inflammation was
observed in
Bioengineered
Sphincter implants
• Harvested post-implant
sphincters capable of
maintaining basal tone,
relaxation, and
contractile activity
Table 2.
Summary of nonclinical study for safety and efficacy of bioengineered sphincters in athymic rodent model.
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neural network innervated into intact aligned muscles. The section displayed
microvasculature and several blood vessels embedded within the implanted
smooth muscles [35].
The myogenic and neuronal components were preserved after implantation. All
the bioengineered constructs were able to generate myogenic spontaneous basal
tone pre- and post-implantation. A rapid and robust relaxation response was
observed against VIP. This relaxation was 50–70% attenuated on pre-treatment of
TTX, indicated that VIP-induced relaxation has both neuronal, as well as myogenic
component. The relaxation was further validated with EFS and resulted in transient
relaxation ultimately recovered to basal tone. The inhibition of nitrergic and VIP-
ergic EFS-induced relaxation (by antagonizing nitric oxide synthesis or receptor
interaction) confirmed the relaxation of enteric nerves results in nitrergic as well as
VIP-ergic inhibitory neurotransmission in the implants. The excitatory neurotrans-
mitter Ach (and partial inhibition on pre-treatment with TTX)-induced contraction
response emulated before and after implantation, confirmed synergistic involve-
ment of both neuronal and myogenic components. Fundamental electromechanical
coupling of smooth muscle was also maintained during implantation, rendering the
implanted IAS physiologically similar to in vivo IAS [35].
This was the first attempt of bioengineering of intrinsically innervated human
IAS constructs. Both of myogenic and neuronal components of constructs were
stable, sustained, viable and synergistically responsive after implantation in
immune-suppressed mice. The study also concluded that bioengineering of intrin-
sically innervated sphincter is feasible, scalable, and customizable to match specific
size and cell population. This leads to one step closer towards bioengineering of
human engineered BioSphincters.
6. Bioengineering of physiologically functional intrinsically innervated
human internal anal sphincter constructs
In previous studies, IAS smooth muscle constructs were engineered [34, 40] and
implanted for cytocompatibility and physiological analysis. These preliminary
studies were proof of concept using human origin SMCs and immortomouse-origin
neural stem cells. To translate the bioengineered sphincter to the clinical realm, it
was essential to use human origin neural cells to engineer IAS sphincters.
The next objective was to develop bioengineering physiologically functional,
intrinsically innervated human IAS tissues, using human origin neural cells and IAS
muscle cells. Therefore, a method was optimized for the isolation of neuronal
progenitor cells (NPCs) from intestinal biopsies of adult human donors. The cell
culture and characterization protocol were standardized to yield an un-
differentiated pure population of enteric neural progenitor cells [33].
Several matrix compositions were evaluated as a carrier for differentiation of
adult enteric NPCs to functional neurons. The type-1 collagen with laminin was
optimized as hydrogel for neural differentiation [41, 42]. The collagen acts as a
matrix for mechanical strength and laminin is important for neuronal development.
The SMCs has the ability to reform the collagen hydrogel into 3D structure due to
matrix metalloproteinase activity [43]. During this restructure of hydrogel from 2D
to 3D, SMCs came into close proximities of NPCs and enhanced the NPCs differen-
tiation. Detail NPCs-SMCs interactions were studied, and it was observed that
mature smooth muscle was essential for the direct differentiation of adult enteric
NPCs [33]. The ratio of NPCs and SMCs were also studied and concluded that
200,000 NPCs/construct with 500,000 SMC/constructs were optimum do generate
a native physiological response [33].
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The constructs responded appropriately to physiologically relevant stimulatory
and inhibitory neurotransmitters during functional analysis. It was validated in
immunocytochemistry, the intrinsically innervated bioengineered construct
exhibited excitatory and inhibitory motor neuronal population. The constructs
displayed characteristics of functional mature contractile IAS smooth muscle as
well. Overall, the human innervated functional IAS sphincter like tissues were
successfully bioengineered and characterized [33].
7. Peri-anal implantation of bioengineered human internal anal
sphincter constructs intrinsically innervated with human neural
progenitor cells
After successful bioengineering of human IAS sphincter-like tissues, it was
essential to evaluate the in vivo safety and functionality. In the next part of the
study, a method was developed for isolation of rectal verge in an athymic rodent
Steps Study objective
(s)
Test article Animal
model
Key outcome (e.g., safety (tumor/tox/
biodistribution), efficacy,
characterization, stability,
degradation)
Study purpose: cell isolation
Isolation of SMC To isolate IAS
smooth muscle
cells (SMC) and
characterization
In vitro
expanded IAS
smooth
muscle cells
Cadaver
human
Smooth muscle cells expressed cell
lineage appropriate phenotype markers
Isolation of neural
progenitor cells
To isolate neural
progenitor cells
and
characterization
In vitro
expanded
neural
progenitor
cells
Cadaver
human
Neural progenitor cells expressed cell
lineage appropriate phenotype markers
Study purpose: bioengineered sphincters
Bioengineered
sphincters with
smooth muscle and
neural progenitor
cells
Characterize the
bioengineered
sphincters
Bioengineered
sphincters
Cadaver
human • Formation of intrinsically
innervated sphincters
• Bioengineered sphincters
exhibited basal tone, relaxation,
and contractile activity
Study purpose: implantation of bioengineered sphincters into rodent
Implantation of
bioengineered
sphincters
Optimization of
the implantation
procedure
Bioengineered
sphincters
athymic
nude
rats
Bioengineered sphincters were
implanted peri-anal site on athymic
nude rats model
Study purpose: end points analysis
Bioengineered
sphincters
histopathology
Analysis of
fibrosis/
inflammation
and functional
activity
Implanted
bioengineered
sphincters
athymic
nude
rats
• No fibrosis or inflammation
was observed in Bioengineered
Sphincter implants
• Harvested post-implant
sphincters capable of
maintaining basal tone,
relaxation, and contractile
activity
Table 3.
Summary of nonclinical study of safety and efficacy of peri-anal implantation of human origin bioengineered
sphincters into athymic rodent model.
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model. Athymic nude mice were larger animal compared to normal mice. The
selection of immune deficient rat for implantation studies of human-origin
bioengineered constructs was to avoid any immune rejection.
The intrinsically innervated human IAS Sphincter were bioengineered using IAS
origin SMCs and enteric NPCs. The developed surgical models were used to implant
bioengineered sphincter into the perianal region of athymic rats for 4 weeks, follow-
ing assessment of viability and functionality [36]. All the rats survived till respective
time points without any obstruction or difficulty with defecation or fecal accumula-
tion. Histopathology analysis concluded the absence of any abscess formations, infec-
tion, or adverse reaction. The implanted constructs were stable and intact at perirectal
tissue of the rat, without any sign of fibrosis or neoplasia. Immuno-histological anal-
ysis with endothelial-specific antigen, vonWillebrand’s factor confirmed neovascu-
larization and formation of several blood vessels. The contractile smooth muscle
phenotype was maintained by exhibiting positive expression to human reactive mus-
cle specific antibodies. Table 3 summarized the detail study design [36].
Pre- and post-implant physiological force measurement studies confirmed dis-
tinct characteristics like native sphincters. The engineered IAS sphincter exhibited
stable spontaneous myogenic basal tone. There was a robust response to different
relaxant and excitatory stimulants, which was persistent after implantation.
This study concluded that for clinical application the bioengineered sphincter
could be used in an additive manner rather than in a replacement manner, where
native compromised IAS sphincter can be supported by transplantation of additional
bioengineered sphincters. In this way, the patient’s own IAS can be preserved and
augmented with additional autologous functional neuro-muscular components [36].
8. Long-term non-clinical study of autologous bioengineered
BioSphincters for the treatment of fecal incontinence
This study aimed to provide data for a large animal model in support of the use
of Bioengineered sphincter as a new therapy to treat FI. These nonclinical studies
were conducted to test the safety and efficacy of using autologous cell
bioengineered sphincters as a regenerative medicine approach for treating induced
FI in rabbits. The study design consisted of four steps. Table 4 summarizes the four
steps including their objectives and key outcomes.
8.1 Selection of a large animal model for nonclinical studies of fecal
incontinence
Currently, there is no model for FI where the defect is specific to the internal
anal sphincter. In humans, the IAS is responsible for 70% of anal basal pressure,
anal closure, and fecal continence. The New Zealand white rabbit (female, 3.0–
3.5 kg at the enrollment of the study) was chosen as an animal model because the
anatomy and the surgical planes of the anal area are similar to humans. The rabbit
was selected as a good model for successful identification and surgical resection of
full thickness biopsies with a successful outcome. Thus, the rabbit is a good large
animal model for our lab to utilize in evaluating FI. The number of animals, exper-
imental protocols, and overall study design used in this study were reviewed and
approved by the Wake Forest Institutional Animal Care and Use Committee before
conducting any component of this study involving animals. Each rabbit was given a
unique identification number that was printed on the cage card. Each rabbit was
identified using a unique identification number. All data collected on each animal
was referenced with the unique animal identification number and tattooed onto the
10
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Steps Study objective(s) Test article Animal
model
Key outcome (e.g., safety
(tumor/tox/
biodistribution),
efficacy,
characterization,
stability, degradation)
Study purpose: developing FI model and autologous cell isolation
IAS hemi-
sphincterectomy
To induce FI Donor IAS
tissue
Female
New
Zealand
rabbits
Lack of fecal hygiene and
significant reduction in
anal basal pressure and
RAIR
Isolation of SMC To isolate autologous
IAS smooth muscle cells
(SMC) characterization
of autologous smooth
muscle
In vitro
expanded IAS
smooth
muscle cells
Female
New
Zealand
rabbits
Smooth muscle cells
expressed cell lineage
appropriate phenotype
markers
Small intestinal
biopsy
To isolate neural
progenitor cells (NPC)
characterization of
autologous NPC
In vitro
expanded
small intestine
neural
progenitor
cells
female
New
Zealand
rabbits
Neural progenitor cells
expressed cell lineage
appropriate phenotype
markers
Study purpose: autologous bioengineered sphincters
Bioengineered
sphincters with
autologous smooth
muscle and neural
progenitor cells
Characterize the
bioengineered
sphincters
Autologous
bioengineered
sphincters
female
New
Zealand
rabbits
Restoration of fecal
hygiene, anal basal
pressure, and RAIR
Study purpose: implantation of engineered autologous bioengineered sphincters to treat FI in rabbits
Implantation of
bioengineered
sphincters
Optimization of the
implantation procedure
Autologous
bioengineered
sphincters
female
New
Zealand
rabbits
The dosage of
bioengineered sphincters
was optimized four
bioengineered sphincters
were implanted on each
rabbit in the treated group
Anal basal pressure
and RAIR
Effects of
bioengineered
sphincters on the
restoration of
continence
Autologous
bioengineered
sphincters
female
New
Zealand
rabbits
Rabbits with induced FI
receiving bioengineered
sphincter implants had
anal basal pressure, and
RAIR restored to normal
baseline, but rabbits with
induced FI in the non-
treated group and sham
surgery group had
consistently reduced anal
basal pressure and RAIR
Study purpose: end points analysis
Blood results Effects of implants on
blood cell counts,
kidney and liver
function, and
electrolytes.
Implanted
bioengineered
sphincters
female
New
Zealand
rabbits
There were no adverse
effects of implants on
blood values
Tissue pathology Effects of experimental
conditions on tissue
pathology
Implanted
bioengineered
sphincters
female
New
Zealand
rabbits
There were no effects of
experimental condition on
local or peripheral
histopathology
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ear of each animal to prevent mix-up. Rabbits were acclimated for at least 6 days
before enrollment in the study [10, 39].
8.2 Study groups
The groups of the study, summarized inTable 5, was developed to assess the post-
implantation safety of bioengineered sphincters in rabbits at three-time points (3, 6, and
12 months). All animals underwent IAS hemi-sphincterectomy to induce FI. Rabbits
were randomly divided into three experimental groups: (1) non-treated group (inconti-
nent control), (2) treated group (received surgical implantation of bioengineered
sphincters 6–8 weeks following sphincterectomy through a surgical opening of the anal
verge), and (3) Sham surgery group (surgical opening of the anal verge was performed
followed by immediate closure without implantation of bioengineered sphincters).
8.2.1 Development of FI
The IAS hemi-sphincterectomy was performed on all the rabbits to induce
passive FI. The development of passive FI was confirmed in each assessment of
fecal hygiene and anorectal pressure. Baseline manometry readings were obtained
on all rabbits before any surgeries. Following hemi-sphincterectomy, anorectal
manometry was performed on all rabbits to confirm passive FI, which was identi-
fied by lack of fecal hygiene and by a significant decrease in anal basal pressure and
RAIR in all rabbits [10, 39].
8.2.2 Bioengineering of autologous BioSphincters
The SMCs were isolated from the IAS harvested during hemi-sphincterectomy.
Isolated cells were characterized by α-smooth muscle actin and smoothelin markers.
Cells stained positive confirming contractile phenotype of smooth muscle cells.
NPCs were isolated from small intestine biopsies. Cells were then characterized by
immunofluorescence and stained positive for p75NTR, Nestin, and Sox2,
confirming neural crest-derived stem cells. Both cell types were expanded for
4 weeks to obtain the required number to form the bioengineered sphincters.
Intrinsically innervated IAS sphincters were bioengineered using both types of
cells as described previously. Bioengineered sphincter products were characterized
using different methods. The presence of aligned smooth muscle cells and the
Steps Study objective(s) Test article Animal
model
Key outcome (e.g., safety
(tumor/tox/
biodistribution),
efficacy,
characterization,
stability, degradation)
Clinical
presentation
Morbidity/mortality Implanted
bioengineered
sphincters
female
New
Zealand
rabbits
There were no effects of
bioengineered sphincter
implantation on morbidity
or mortality
IAS histopathology Fibrosis/inflammation Implanted
bioengineered
sphincters
bioengineered
sphincter
female
New
Zealand
rabbits
No definitive difference
between bioengineered
sphincter implants and
naïve. No evidence of
neoplasia
Table 4.
Summary of nonclinical study of safety and efficacy of bioengineered sphincters.
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Study groups (no. of
rabbits)
Baseline
manometry
Sphincterectomy to
induce FI
Manometry post
sphincterectomy
4–6 weeks post
sphincterectomy
1 month 3 months 6 months 12 months
Non-treated group (11) ✓ ✓ ✓ No treatment Manometry post sphincterectomy
Treated group (10) ✓ ✓ ✓ Implant bioengineered
sphincters
Manometry post implant
Sham surgery group (5) ✓ ✓ ✓ Sham surgery Manometry post sham
Table 5.
Study groups for the non-clinical study.
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differentiated functional neural network was confirmed via immune-reactivity
against smoothelin and βIII tubulin. These results further validated via positive
expression of smoothelin and βIII tubulin qPCR. Engineered IAS sphincters were
tested for physiological functionality. The engineered tissues able to generate the
spontaneous basal tone and exhibited a robust stable response following pharmaco-
logical or electrical stimuli. The bioengineered autologous BioSphincters were
implanted adjacent to IAS tissues into the respective rabbits [10, 39].
8.2.3 Implantation and restoration of fecal continence
Anorectal manometry is a technique used to measure contractility in the anus
and rectum. Anorectal manometry was performed initially at baseline prior to any
surgery. These measurements reflected the control state for all animals in this study.
Anorectal manometry was performed prior to any surgery (before animals went for
any procedure) to record the baseline, and 1 month following IAS hemi-
sphincterectomy (biopsy), then at 3, 6, and 12 months in each experimental group.
8.2.3.1 Restoration of anorectal pressure
IAS hemi-sphincterectomy resulted in a significant decrease in anal basal pres-
sure and RAIR compared to baseline (no surgery), supporting the validity of the
induced-incontinence model. In the sham surgery group, anal basal pressure and
RAIR were not improved and were comparable to readings from rabbits in the non-
treated group. Compared to baseline, the basal pressure in non-treated and sham
group was decreased by 41% (p < 0.0001) after 1 month of hemi-sphincterectomy
and remained low up to study time point of 12 months. Similarly, RAIR was also
reduced by 50.9% from the baseline (p < 0.0001). It remained low in
non-treated group (49.2%) and sham groups (40.0%) compared to baseline till the
study time point.
This reduced anorectal functionality was restored within 1-month post-
implantation of autologous BioSphincters in the treated group. The resting pressure
was returned to baseline after 4 weeks of implantation and remained similar up to
12 months. RAIR was restored by 88% in initial 1 month and improved within
3 months and sustained till 12 months. The restoration of basal pressure and RAIR
were significantly higher (p < 0.0001) than values observed in the non-treated
group and sham groups.
8.2.3.2 Improvement in fecal hygiene
The IAS hemi-sphincterectomy affected fecal hygiene of the rabbits. This was
evident from messy rabbit cages as feces were dispersed over the whole area of the
cage. There was a definite lack of anal area hygiene as the area was always covered
in a thin layer of feces. After implantation, the fecal hygiene returned to normal
with a clean anal area and normal defecatory movement.
An improvement in defecatory activity was observed as early as 3 weeks after
implantation of the bioengineered sphincters. Stool consistency returned to a firm
pellet, similar to what was observed before FI was induced by the sphincterectomy.
8.2.3.3 Histopathology assessment
The post-implant harvested tissues displayed intact BioSphincter after 12 months
of implantation. The presence of a thick continuous sheet of muscles innervated with
neuronal network validated the manometry outcomes. There was the absence of any
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fibrosis or avascular collagen around the implant, indicating no foreign-body reaction
with the implants. Pathologic findings in this study were generally minor and
consisted primarily of a low incidence of background changes and minor changes
attributable to implantation. There was no evidence of neoplasia. These results con-
firmed that the bioengineered sphincters were viable and functional in vivo with the
maintenance of both the muscle and neural components [10, 39].
In this study, passive Fi was successfully developed in the large animal model.
The bioengineered intrinsically innervated IAS constructs from the autologous cells
retrieved at biopsy. The IAS constructs were bioengineered and implanted after 6–
8 weeks after harvesting the cells (Figure 2A); then, one by one, four bioengineered
sphincters were implanted at the anal site (Figure 2B). The four bioengineered
sphincters were stacked together at the site (Figure 2C). After 12 months of
implantation, implanted bioengineered sphincters appeared intact as one tissue at
the site (Figure 2D).
The animals resumed normal activity and defecatory bowel movement. There
was no indication of any rectal outlet obstruction or anal stenosis. Anorectal
manometry was performed on the animals monthly beginning 6 weeks after
implantation. The animals exhibited a reinstated basal tone and RAIR. Animals were
maintained and monitored up to 12 months after implantation. At each endpoint,
after euthanasia, the harvested implant was tested. Results show that the construct
maintained physiological functionality. The tests show that both muscle and neural
type of cells maintained their physiological function. In other experiments, we have
demonstrated that the cells of the implant stayed within the implant and did not
migrate outside the location of the implant.
9. Conclusion
Regeneration of an intrinsically innervated function IAS sphincter is a promising
approach for long-term relief from passive FI. The IAS muscle and neural cells
synergized in collagen-laminin hydrogel as a 3D sphincter like architecture, mim-
icking the native IAS cell orientation and innervation. The bioengineering process
has been optimized, scaled up for clinical application using human origin cells. The
signaling pathways for sphincter tone and contraction were characterized. The
bioengineered sphincter able to generate spontaneous tone and response to differ-
ent pharmacological agents was comparable to human IAS. The stability, viability
and cytocompatibility analysis of engineered sphincters were carried out in vitro
and in vivo conditions. The step-wise pre-clinical assessment of engineered
Figure 2.
Different stages from bioengineered sphincter to implantation; (A) bioengineered sphincter; (B) implantation
of two bioengineered sphincters; (C) 4 implanted bioengineered sphincters; and (D) implanted bioengineered
sphincter after euthanasia (after 12 months of implantation).
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autologous BioSphincters confirmed biocompatibility as IAS sphincter substitute,
without any adverse effect. The implanted autologous BioSphincters vascularized,
integrated with the impaired native IAS and regenerated stable, circularly oriented
IAS muscle population, innervated with the neural network. The regeneration
approach provided immediate symptomatic relief by restoration fecal hygiene. We
have developed a large animal model of passive fecal incontinence and demon-
strated sustained restoration of fecal continence, and restoration of basal tone and
restoration of RAIR in this model after implantation of engineered autologous
intrinsically innervated internal anal sphincter (IAS) BioSphincters. In a clinical
scenario, this innovative approach will be able to reinstate continence, by providing
an additive functional intrinsically innervated IAS bioengineered from the patient’s
cells.
As summary, regeneration, and implantation of the IAS BioSphincter will bene-
fit a large socially distressed segment of the population via restoration of physio-
logical function of the IAS, resolve FI, and improving quality of life.
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